Press Releases from December 13, 2017
advertisement
- FDA Approves Sanofi’s Admelog® (insulin lispro injection).
- Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes. See also French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma.